Can a drug stop amyloid damage after a heart transplant?

NCT ID NCT05489523

Ongoing Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the drug tafamidis can safely stop the progression of ATTR amyloidosis in people who have already received a heart transplant. About 25 stable patients will take tafamidis daily for 12 months. Researchers will measure changes in blood protein levels, nerve function, and quality of life to see if the drug helps control the disease outside the heart.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tafamidis
What this could lead to: If it works, this could show that tafamidis safely prevents or slows amyloid buildup in nerves and the gut after a heart transplant.
What could go wrong: This is a small, early-phase study with only 25 people and no placebo group, so results may not apply broadly. Tafamidis may not work as well in transplant patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN CARDIAC AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial amyloid neuropathy wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSTHYRETIN CARDIAC AMYLOIDOSIS

Contacts and locations

Locations

Cedars-Sinai

Beverly Hills, California, 90211, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Columbia University Medical Center

New York, New York, 10032, United States
UT Southwestern Medical Center

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.